Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Huang T, Zhang S, Dai DF, Wang BS, Zhuang L, Huang HT, Wang ZF, Zhao JS, Li QP, Wu SP, Wang X, Zhang WD, Zhao ZH, Li H, Zhang YP, Yang XL, Jiang XY, Gou JB, Hou LH, Gao LD, Feng ZC. Huang T, et al. Among authors: wang zf, wang x, wang bs. Lancet Respir Med. 2023 Aug;11(8):698-708. doi: 10.1016/S2213-2600(23)00129-7. Epub 2023 May 17. Lancet Respir Med. 2023. PMID: 37209700 Clinical Trial.
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD, Li JX, Liu J, Wang HM, Zhou GH, Li J, Wu D, Chen X, Feng Y, Qi XY, Wang X, Gou JB, Ma TL, Yang XY, Xu LF, Wan P, Zhu T, Wang ZF, Zhu FC; CanSino COVID-19 Study Group. Wu JD, et al. Among authors: wang x, wang zf, wang hm. Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8. Epub 2023 May 19. Lancet Infect Dis. 2023. PMID: 37216958 Clinical Trial.
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng GW, Wang ZF, He P, Lan QY, Ni L, Yang YZ, Wang CF, Cui TT, Huang LL, Yan YQ, Jiang ZW, Yang Q, Yu BW, Han X, Chen JJ, Yang SY, Yuan L, Zhou LY, Liu G, Li K, Huang Z, Zhao JC, Hu ZY, Xie ZQ. Feng GW, et al. Among authors: wang zf, wang cf. Hum Vaccin Immunother. 2023 Aug;19(2):2262635. doi: 10.1080/21645515.2023.2262635. Epub 2023 Oct 26. Hum Vaccin Immunother. 2023. PMID: 37881130 Free PMC article. Clinical Trial.
Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard.
Guan L, Mao Q, Tan D, Liu J, Zhang X, Li L, Liu M, Wang Z, Cheng F, Cui B, He Q, Wang Q, Gao F, Wang Y, Bian L, Wu X, Hou J, Liang Z, Xu M. Guan L, et al. Front Immunol. 2023 Feb 14;14:1107639. doi: 10.3389/fimmu.2023.1107639. eCollection 2023. Front Immunol. 2023. PMID: 36865542 Free PMC article.
The Role of Beta2-Microglobulin in Central Nervous System Disease.
Liu ZY, Tang F, Yang JZ, Chen X, Wang ZF, Li ZQ. Liu ZY, et al. Among authors: wang zf. Cell Mol Neurobiol. 2024 May 14;44(1):46. doi: 10.1007/s10571-024-01481-6. Cell Mol Neurobiol. 2024. PMID: 38743119 Free PMC article. Review.
916 results